Standard Contracts
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 31st, 2022 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • Massachusetts
WHEREAS, the Company and the Executive previously entered into an employment agreement dated as of December 7, 2020 pursuant to which the Executive served as General Counsel and Senior Vice President of Legal Affairs of the Company (the “Prior Agreement”);
AMENDMENT #2 TO AMENDED AND RESTATED AGREEMENTAmendment to Amended and Restated Agreement • March 31st, 2022 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • New York
This Amendment to Amended and Restated Agreement (this “Amendment”) is entered into as of November 12, 2021 (the “Amendment #2 Effective Date”) by and between Finch Therapeutics, Inc., a Delaware corporation having its principal office at 200 Inner Belt Road, 4th Floor, Somerville, Massachusetts 02143 (“Finch”), and Takeda Development Center Americas, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, having its principal office at 95 Hayden Avenue, Lexington, MA 02421 (“Takeda”).
AMENDMENT NO. 1 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 31st, 2022 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This AMENDMENT NO. 1 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “New Amendment”) is made as of March 18, 2021, by and between Finch Therapeutics Group, Inc., a Delaware corporation (“FTG”, together with all subsidiaries and affiliates hereinafter referred to as the “Company”), and Joseph Vittiglio (the “Executive”) This New Amendment shall amend that certain AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT, dated as of March 12, 2021 (the “Prior Amendment”), by and between the Company and the Executive.
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 31st, 2022 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances)
THIS AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is made as of the Effective Date by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 200 Oak Street, SE, Suite 280, Minneapolis, Minnesota 55455 (the “University”), and the Licensee identified below.
Release AgreementRelease Agreement • March 31st, 2022 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • Massachusetts
I, Zain Kassam, understand and agree completely to the terms set forth in this Release Agreement (the “Release”) and in the Amended and Restated Executive Employment Agreement (the “Employment Agreement”) dated March 12, 2021, by and between Finch Therapeutics Group, Inc. (“Company”) and me, as a result of my voluntary resignation without Good Reason effective on November 5, 2021 (the “Termination Date”). I understand that I am not entitled to any payments set forth in Section 1 below if I do not sign this Release and return it to Company pursuant to the terms set forth herein. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Employment Agreement.
